Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642174 · ClinicalTrials.gov registry record · Phase 2
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00642174 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT00642174, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers. The study will compare platelet function following a prasugrel loading dose and 1 week of prasugrel maintenance therapy with high-dose clopidogrel loading dose and 1 week of high-dose clopidogrel maintenance therapy in patients with drug treated type 2 diabetes mellitus who have coronary artery disease. Various assays of platelet function will be used in this study. Platelet function will be studied using the following assays: Accumetrics VerifyNowTM P2Y12, Light Transmittance Aggregometry (LTA), Vasodilator-associated stimulated phosphoprotein (VASP), and Thromboelastography (TEG)-platelet mapping.
Interventions
- DRUG Clopidogrel
- DRUG prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642174
The ClinicalTrials.gov registry entry for NCT00642174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00642174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642174 about?
NCT00642174 is a clinical study titled "Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)". This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers. The study will compare platelet function following a prasugrel loading dose and 1 week of prasugrel maintenance t...
What is the current status of trial NCT00642174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00642174?
The interventions under investigation include: Clopidogrel (DRUG), prasugrel (DRUG).
Who is sponsoring clinical trial NCT00642174?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.